Short-term Hemodynamic Effects Of Intravitreous Injection Of 0.5 Mg Ranibizumab

Objective: To observe the short-term retrobulbar hemodynamic effects of intravitreal injection of anti-VEGF drug,0.5 mg ranibizumab,in age-related macular degeneration(AMD)patients.Methods: A total of 34 eyes of 34 patients diagnosed as AMD at the Fourth Affiliated Hospital of China Medical University from February 2017 to December 2017 was selected as study subjects(treatment group)and 34 eyes of 34 normal cases matched with age and sex as a control group.In the treatment group,AMD patients received monthly intravitreal injection of anti-VEGF drug,0.5 mg ranibizumab,or PRN regimen based on the stability of choroidal new vascularization(CNV).Blood pressure,intraocular pressure(IOP),and total hemodynamic parameters of ophthalmic artery(OA),central retinal artery(CRA)and short posterior ciliary artery(sPCA)were observed before treatment,2 hours,1 day and 30 days after treatment.Peak systolic blood flow velocity(PSV),end-diastolic blood flow(EDV)and resistance index(RI)were measured,respectively.Data processing and statistical analysis were carried out by using SPSS 24.0 statistical software.Paired t-test was used to analyze the data.Results: There was no significant statistical difference in OA blood flow parameters between the AMD group and the control group(P > 0.05).There was significant statistical difference in the partial blood flow parameters of CRA and sPCA between the AMD group and the control group(P < 0.05);PSV,EDV of OA,PSV,EDV and RI of CRA in treatment eyes at 2 hours after intravitreous injection were significant lower than those before injection(P < 0.05);PSV of every vessels,the EDV of OA and CRA in treatment eyes one day after intravitreous injection were significantly lower than those before injection(P < 0.05).The PSV of OA after 30 days was lower than that before injection(P < 0.05).There was no significant difference in other blood flow parameters after injection(P < 0.05).Conclusions: Intravitreous injection of anti-VEGF drug,0.5 mg ranibizumab,may affect blood flow velocity in the posterior portion of eyeballs in short term(within 1 week).Most of the retrobulbar blood flow parameters go back to normal one month after injection.